Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ 7.13MDepreciation, Amortization & Accretion
VS
Market
Sector
Industry
History
$ 9.96Close
$ 2.51 - $ 9.97 52-Week Range
Ticker Information
Ticker
FDMTCompany Name
4D MOLECULAR THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQ4D MOLECULAR THERAPEUTICS INC - Depreciation, Amortization & Accretion Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
FDMT - DepAmor Historical data
| Date | Depreciation, Amortization & Accretion |
|---|---|
| 6/30/2025 | $ 7.13M |
| 3/31/2025 | $ 6.87M |
| 12/31/2024 | $ 6.71M |
| 9/30/2024 | $ 6.43M |
| 6/30/2024 | $ 6.13M |
| 3/31/2024 | $ 5.93M |
| 12/31/2023 | $ 5.75M |
| 9/30/2023 | $ 5.62M |
| 6/30/2023 | $ 5.11M |
| 3/31/2023 | $ 4.51M |
Key Performance Insights, Last 5 Years
- 4D MOLECULAR THERAPEUTICS INC's latest trailing twelve months (TTM) DepAmor stands at $ 1.44M.
- Over the past 5 years, 4D MOLECULAR THERAPEUTICS INC's average DepAmor has been $ 4.81M.
- The median DepAmor for 4D MOLECULAR THERAPEUTICS INC during this period was $ 5.11M
- 4D MOLECULAR THERAPEUTICS INC reached its highest DepAmor over the past 5 years at $ 7.13M.
- The lowest DepAmor recorded by 4D MOLECULAR THERAPEUTICS INC in the same timeframe $ 1.44M
4D MOLECULAR THERAPEUTICS INC's DepAmor vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
DepAmor Benchmarks
Similar metrics to DepAmor:
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- Depreciation and Amortization Margin - [Calculation] The company’s deprecation and amortization [DepAmor] expressed as a percentage of [Revenue].
- Net Cash Flow - Operations - [Cash Flow Statement] Cash flow from operations represents the amount of cash inflow (outflow) that a company generates (consumes) from operating activities. Similar to Net Income [NetIncCmn] but harder to manipulate and ignoring effects of non-cash charges like depreciation.
- Stock Based Compensation - [Cash Flow Statement] Stock Based Compensation, also called Share Based Compensation or Equity Compensation, is a method of paying directors, executives and employees with equity in the business. As non-cash expense, this element is added back when calculating net cash generated by operating activities [NCFO].
- Earnings per Share - [Income Statement] Earnings per Share as calculated and reported by the company. Approximates to the amount of net income [NetIncCmn] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
Definition of Depreciation, Amortization & Accretion
[Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.FDMT - Depreciation, Amortization & Accretion, Last 5 years
$ 1.44M
Minimum
Dec 31, 2020
$ 7.13M
Maximum
Jun 30, 2025
$ 4.81M
Average
$ 5.11M
Median
DepAmor Benchmark AnalysisMarket
The chart above depicts the distribution of DepAmor for companies in the Total Stock Market. The average DepAmor of the companies is $ 24.07M with a standard deviation of $ 33.58M.
The following table provides additional summary stats:
DepAmor in the Market:
| filtered constituents | 3.16K |
|---|---|
| min | $ -81M |
| max | $ 135.97M |
| average | $ 24.07M |
| median | $ 6.83M |
| std | $ 33.58M |